Early lymph node check is saving lives in melanoma patients
19 October 2017
Research presented this week at the 9th World Congress of Melanoma supports the updated guideline recommendation that sentinel lymph node biopsy be performed in more patients newly diagnosed with melanoma, as it has the potential to save lives due to the information the procedure provides.
This biopsy, which looks for cancer cells in the lymph nodes, can identify patients whose melanoma has spread beyond the site on the skin (Stage III melanoma) and who may be suitable to receive the new generation of anti-melanoma drugs.
The recently published Australian Clinical Practice Guidelines for the Diagnosis and Management of Melanoma recommends that “sentinel lymph node biopsy should be considered for all patients with melanoma greater than 1 mm in thickness and for patients with melanoma greater than 0.8 mm with other high risk pathological features to provide optimal staging and prognostic information and to maximise management options for patients who are node positive”.
“We know patients who have melanoma cells present in their draining lymph nodes (Stage III) are up to three times more likely to die from their melanoma than patients where the lymph nodes are clear,” says David Gyorki, a consultant surgeon and melanoma specialist at the Peter MacCallum Cancer Centre.
“For some time, we’ve known that sentinel lymph node biopsy is an excellent way to identify those patients who have a higher risk of having their disease progress, and with the new drugs we have gained the tools to respond and to reduce this risk.
“On the horizon, we will have access to effective, well tolerated drug therapies that can reduce the risk of relapse and, using sentinel lymph node biopsy to identify appropriate patients, the data indicate that this strategy is saving lives.”
For most patients diagnosed with melanoma, their disease is localised and effectively treated with surgery; however, some patients’ disease will progress. Of the 14,000 Australians diagnosed with melanoma each year, almost 15% will die from their disease.
Findings from recent clinical trials have demonstrated a major improvement in survival for patients with Stage III melanoma using drug therapy after surgery with the aim to prevent the melanoma from appearing in distant organs (Stage IV disease).
In one such clinical trial, known as COMBI-AD, patients who received a combination of targeted therapies (dabrafenib and trametinib) decreased the chance of their melanoma progressing by 53% compared to the current standard therapy of ‘watch and wait’.
“We encourage clinicians to inform their patients about sentinel lymph node biopsy so that patients can properly understand their risk of recurrence and death from melanoma, and therefore discuss the option of further drug therapy” says Professor Georgina Long, Medical Oncologist and Co-Medical Director of Melanoma Institute Australia.
The 9th World Congress of Melanoma is underway in Brisbane, October 18 – 21.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.
Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.